Skip to main content

Table 2 Multigene predictors of sensitivity to chemotherapy

From: Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction

Authors Number of casesa Regimen Chemotherapy Chemosensitivity evaluation Technology Method Signature NPV PPV Accuracy
Chang et al. [116] 24 discovery
6 validation
Neoadjuvant Docetaxel Clinical response cDNA microarray Supervised 92 genes 83% 92% 88%
Ayers et al. [90] 24 discovery
12 validation
Neoadjuvant T/FAC pCR cDNA microarray Supervised 74 genes 73% 100%
(3/3)
78%
Iwao-Koizumi et al. [91] 44 discovery
26 validation
Neoadjuvant Docetaxel Clinical response High-throughput RT-PCR Supervised 85 genes 90.9% 73.3% 80.7%
Gianni et al. [70] 89 discovery
92 validation
Neoadjuvant TA pCR qRT-PCR/DNA microarray Supervised 86 genes - - -
Hess et al. [92] 82 discovery
51 validation
Neoadjuvant T/FAC pCR cDNA microarray Supervised 30 genes 96% 52% 76%
Thuerigen et al. [93] 52 discovery
48 validation
Neoadjuvant G-ET pCR cDNA microarray Supervised 512 genes 95% 64% 88%
Farmer et al. [103] 63 Neoadjuvant FEC pCR cDNA microarray Metagene approach Stromal metagene 81% 57% 65%
  1. aNumber of cases in discovery and validation sets. FEC, fluorouracil, epirubicin, and cyclophosphamide; G-ET, gemcitabine, epirubicin, and docetaxel; NPV, negative predictive value; pCR, pathological complete response to neoadjuvant chemotherapy; PPV, positive predictive value; qRT-PCR, quantitative reverse transcriptase-polymerase chain reaction; RT-PCR, reverse transcriptase-polymerase chain reaction; TA, taxanes and anthracycline (that is, paclitaxel and doxorubicin); T/FAC, paclitaxel/fluorouracil, doxorubicin, and cyclophosphamide.